Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 946,145
  • Shares Outstanding, K 103,517
  • Annual Sales, $ 57,880 K
  • Annual Income, $ -519,020 K
  • EBIT $ -534 M
  • EBITDA $ -524 M
  • 60-Month Beta 1.97
  • Price/Sales 16.49
  • Price/Cash Flow N/A
  • Price/Book 1.08

Options Overview Details

View History
  • Implied Volatility 91.16% ( +0.79%)
  • Historical Volatility 81.57%
  • IV Percentile 93%
  • IV Rank 70.63%
  • IV High 106.41% on 11/15/24
  • IV Low 54.50% on 08/21/24
  • Put/Call Vol Ratio 0.19
  • Today's Volume 988
  • Volume Avg (30-Day) 2,230
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 49,460
  • Open Int (30-Day) 46,577

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.27
  • Number of Estimates 10
  • High Estimate -0.89
  • Low Estimate -1.43
  • Prior Year -1.06
  • Growth Rate Est. (year over year) -19.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.30 +15.42%
on 03/04/25
12.84 -25.39%
on 02/20/25
-1.12 (-10.47%)
since 02/14/25
3-Month
8.30 +15.42%
on 03/04/25
13.34 -28.19%
on 01/07/25
-3.55 (-27.04%)
since 12/17/24
52-Week
8.30 +15.42%
on 03/04/25
28.54 -66.43%
on 03/21/24
-18.72 (-66.15%)
since 03/15/24

Most Recent Stories

More News
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 9.58 (+4.81%)
Intellia Therapeutics Delivers a Q4 Beat

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue.

NTLA : 9.58 (+4.81%)
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

NTLA : 9.58 (+4.81%)
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next...

CRSP : 42.82 (+1.66%)
NTLA : 9.58 (+4.81%)
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

NTLA : 9.58 (+4.81%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 33.02 (+0.76%)
JNJ : 162.84 (+0.02%)
VRTX : 513.76 (+1.78%)
SNDX : 13.04 (+0.69%)
ABBV : 214.47 (+1.27%)
GERN : 1.7400 (+6.10%)
RHHBY : 44.2400 (+2.27%)
PFE : 26.05 (+1.28%)
NTLA : 9.58 (+4.81%)
BMY : 59.99 (+1.66%)
BIIB : 143.54 (+2.94%)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 9.58 (+4.81%)
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

ARKG : 23.46 (+3.12%)
IBB : 136.10 (+1.42%)
XBI : 88.29 (+1.33%)
NTLA : 9.58 (+4.81%)
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

NTLA : 9.58 (+4.81%)
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

NTLA : 9.58 (+4.81%)

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 10.98
2nd Resistance Point 10.43
1st Resistance Point 10.01
Last Price 9.58
1st Support Level 9.04
2nd Support Level 8.49
3rd Support Level 8.07

See More

52-Week High 28.54
Fibonacci 61.8% 20.81
Fibonacci 50% 18.42
Fibonacci 38.2% 16.03
Last Price 9.58
52-Week Low 8.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar